Carcinomas News and Research

RSS

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

Study suggests new targets for treating rare genetic disorder and cancer

The combined action of two enzymes, Srs2 and Exo1, prevents and repairs common genetic mutations in growing yeast cells, according to a new study led by scientists at NYU Langone Medical Center.

2 Jun 2014

International study provides hope to patients with advanced prostate cancer

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer.

26 May 2014

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014.

15 May 2014

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.

21 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

Stowers team reports genome-wide analysis of genes that drive cell division in multicellular organism

In textbooks, the grand-finale of cell division is the tug-of-war fought inside dividing cells as duplicated pairs of chromosomes get dragged in opposite directions into daughter cells.

3 Apr 2014

Scientists identify new biomarker linked to non-small cell lung cancer, head and neck cancers

A team led by a scientist from the Florida campus of The Scripps Research Institute has identified a new biomarker linked to better outcomes of patients with head and neck cancers and non-small cell lung cancer. The work could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.

3 Apr 2014

Scientists identify two markers that predict patient's resistance to radiation therapy for cancer

An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck.

28 Mar 2014

Novel feedback provides mechanistic link between chronic inflammation and carcinogenesis

Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich have discovered a novel feedback mechanism that provides a mechanistic link between chronic inflammation and carcinogenesis.

20 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

Proteomics identifies possible RCC biomarkers

Proteomic analysis has identified significant differences between the proteins expressed in renal cell carcinoma samples and in healthy renal tissue, UK researchers report.

17 Mar 2014

Second common type of breast cancer appears to be good candidate for personalized treatment approach

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.

26 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Driver mutations found in more than half of adenosquamous lung carcinomas

Analysis of a large cohort of Chinese patients with adenosquamous lung carcinoma has identified known mutant kinases in more than half of the tumours, researchers report in the Journal of Thoracic Oncology.

19 Feb 2014

Two oncogenes work together to sustain population of cells in lung squamous cell carcinoma

Patients with a common form of lung cancer — lung squamous cell carcinoma — have very few treatment options. That situation may soon change.

10 Feb 2014

Findings expand treatment options for hormone-dependent breast cancer

According to the United States Centers for Disease Control and Prevention, breast cancer is the most common cancer in women. For patients whose breast cancers are hormone-dependent, current treatment focuses on using drugs that block estrogen (a type of hormone) from attaching to estrogen receptors on tumor cells to prevent the cells from growing and spreading.

5 Feb 2014

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

A common surgery for non-melanoma skin cancer, known as Mohs surgery typically achieves excellent results but can be a long process, as the surgeon successively removes the area of concern until the surrounding tissue is free of cancer.

29 Jan 2014

Foundation Medicine announces discovery of high incidence of ERBB2 alterations in MPUC patients

Foundation Medicine, Inc. today announced the discovery of a high incidence of ERBB2 (HER2) extracellular domain alterations in patients with micropapillary urothelial carcinoma, a particularly aggressive form of urinary bladder cancer, using FoundationOne. The research was published in the current edition of Clinical Cancer Research.

10 Jan 2014